Wilson Therapeutics

Kempen is pleased to announce that it acted as Joint Bookrunner in the 10% capital increase by Wilson Therapeutics, thereby raising SEK 244 million, and placing another SEK 157m in existing shares

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101 (bis-choline-tetrathiomolybdate), is in development as a novel treatment for Wilson’s Disease, a rare genetic disorder in which copper builds up in the body causing severe brain and liver related symptoms. WTX101 has been successfully evaluated in a Phase 2 clinical study and a pivotal Phase 3 study, of which the design has been approved by the FDA, will start early 2018. Wilson Therapeutics was founded in 2012 and is listed in the Mid Cap segment on Nasdaq Stockholm since 2016.

-  Placement of 2,572,024 new shares, representing 10% of Wilson’s pre-deal outstanding share capital, at an issue price of SEK 95 per share, resulting in gross proceeds of  SEK 244 million

-  A pre-launch market sounding exercise with existing shareholders and potential new investors resulted in substantial, high-quality anchor demand, covering a large majority  of the transaction

- The accelerated book-building process generated strong demand from reputable, international and Swedish institutions and sector specialist funds, such as Oppenheimer,   Polar Capital, Sphera Funds Management, Granite Point Capital Management and Handelsbanken, resulting in a multiple times covered order book

- As a result of the strong demand, existing shareholders Abingworth and MVM accepted to sell in total 1,650,000 existing shares to one of the institutional investors  expressing an interest to participate at the same price as the new shares, for total proceeds of SEK 157m

-  Kempen was involved in more than 75% of the final allocations with a strong focus on bringing US and UK specialist investors to the company

-  Transaction proceeds are envisaged to be used to fund the currently planned clinical program, preparations for the future market launch of WTX101, evaluation of additional pre-clinical and clinical activities and exploratory work in follow-on indications